STTK
Shattuck Labs, Inc.
There isn't enough reported data to score STTK yet.
STTK Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Under pressure | |
| Unavailable | |
| Unavailable |
STTK's revenue and profitability are currently under pressure. There isn't enough data to rate its cash flow and balance sheet.
STTK PE Valuation
STTK has no meaningful PE right now: it lost money over the past year.
STTK Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Growth | |
| -- | |
| Limited | |
| Low |
Analysts expect STTK's revenue to grow, with its earnings and profitability holding steady. However, they disagree widely on these estimates.
STTK Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.56 | +$0.46 |
| Q2 2026 | -$0.56 | +$0.65 |
| Q1 2026 | -$0.68 | +$0.71 |
| Q4 2025 | -$0.82 | +$0.67 |
| Q3 2025 | -$1.02 | +$0.51 |
| Q2 2025 | -$1.21 | +$0.64 |
| Q1 2025 | -$1.39 | +$0.54 |
| Q4 2024 | -$1.49 | +$0.56 |
STTK is still losing money, but far less than before: $0.56 per share over the past year, against $2.43 at its worst in late 2020.
STTK Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2025 | $1M | -67% |
| Q3 2024 | $3M | +337% |
| Q2 2024 | $1.6M | +705% |
| Q1 2024 | $1.1M | +1856% |
| Q4 2023 | $714K | +83% |
| Q3 2023 | $686K | +224% |
| Q2 2023 | $200K | +300% |
| Q4 2022 | $390K | -99% |
STTK's revenue has slid since its 2021 peak: $0 last quarter, down 100% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2025 | -1072% | -474 points |
| Q3 2024 | -598% | +3571 points |
| Q2 2024 | -1427% | +9946 points |
| Q1 2024 | -1798% | +36204 points |
| Q4 2023 | -2654% | +4083 points |
| Q3 2023 | -4169% | +7732 points |
| Q2 2023 | -11374% | +43943 points |
| Q1 2023 | -38002% | N/A |
STTK's operating margin was −1072% last quarter, up 1583 points from the same quarter a year ago.
STTK Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$17.5M | -$8.5M |
| Q1 2026 | -$13.4M | -$1.4M |
| Q4 2025 | -$8.5M | +$8.9M |
| Q3 2025 | -$9M | +$7.1M |
| Q1 2025 | -$12M | +$4.1M |
| Q4 2024 | -$17.4M | +$2.1M |
| Q3 2024 | -$16.1M | +$643K |
| Q2 2024 | -$10.9M | +$8M |
STTK has burned cash in almost every quarter: −$48M over the past year, against −$56M the year before.
STTK Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +16% | +17.5M shares |
| 1 year | +154% | +78.8M shares |
| 3 years | +206% | +87.3M shares |
| 5 years | +210% | +87.9M shares |
| Available history | +579% | +111M shares |
STTK has 130M diluted shares, up 154% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2021 | — |
| Q2 2020 | — |
| Q1 2020 | — |
| Q4 2019 | — |
STTK Net Leverage
STTK's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
STTK Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 39.6 | Neutral |
| Stochastic | 10.1 | Oversold |
STTK's weekly RSI is 40 (neutral) and its Stochastic is 10 (oversold).
STTK PE vs Healthcare Sector
STTK has no meaningful PE right now: it lost money over the past year.
STTK Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $5.58 | 14% below |
| 20 week MA | $6.43 | 25% below |
| 50 week MA | $5.68 | 15% below |
| 100 week MA | $3.48 | 38% above |
| 200 week MA | $3.90 | 23% above |
STTK has slipped below its 8-, 20- and 50-week averages, though it's still 23% above its 200-week average.
STTK Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $19.4 | $57.6 | +198% |
| 2021 | $57.6 | $8.90 | -85% |
| 2022 | $8.90 | $2.41 | -73% |
| 2023 | $2.41 | $7.13 | +196% |
| 2024 | $7.13 | $1.24 | -83% |
| 2025 | $1.24 | $3.35 | +170% |
| 2026 YTD | $3.35 | $4.81 | +44% |
STTK's yearly returns have swung widely, from +198% in 2020 to −85% in 2021. It's up 44% so far in 2026.